Liquidia (NASDAQ:LQDA) Director Sells $286,061.80 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 3,596 shares of the firm’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $79.55, for a total transaction of $286,061.80. Following the sale, the director owned 776,477 shares in the company, valued at approximately $61,768,745.35. This trade represents a 0.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Liquidia Price Performance

NASDAQ:LQDA traded down $0.26 during midday trading on Tuesday, hitting $84.17. The company had a trading volume of 369,446 shares, compared to its average volume of 1,804,077. The company has a market capitalization of $7.48 billion, a PE ratio of 601.30 and a beta of 0.55. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52-week low of $16.82 and a 52-week high of $91.10. The stock’s fifty day moving average price is $71.77 and its 200-day moving average price is $50.58.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. As a group, research analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on LQDA. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Friday, July 17th. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Finally, Needham & Company LLC lifted their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.18.

Institutional Investors Weigh In On Liquidia

Several large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia in the 4th quarter worth approximately $25,000. Covestor Ltd lifted its holdings in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Liquidia during the 2nd quarter worth $25,000. Fluent Financial LLC acquired a new stake in shares of Liquidia during the second quarter valued at about $287,000. Finally, Fulcrum Equity Management acquired a new stake in shares of Liquidia during the second quarter valued at about $399,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: LifeSci Capital maintained its Buy rating on Liquidia, supporting the bullish view that the company’s pipeline and commercial prospects can drive further appreciation. LifeSci Capital sticks to Buy rating
• Positive Sentiment: HC Wainwright expressed a positive view of Liquidia’s fiscal 2027 earnings outlook, suggesting analysts anticipate continued earnings growth as YUTREPIA progresses. HC Wainwright positive FY2027 view
• Positive Sentiment: Buckley Capital Advisors’ investor letter argued that Liquidia could have more than 50% upside, citing an upcoming YUTREPIA ruling and possible buyout interest. These are potential catalysts rather than confirmed events. Buckley Capital investor letter
• Neutral Sentiment: Market commentary highlights a debate over Liquidia’s fair value, with strong growth potential balanced by patent and litigation-related risks. Liquidia fair value debate
• Negative Sentiment: Director Stephen M. Bloch sold 175,000 shares in two transactions for approximately $14.95 million. The sales reduced his direct ownership to 501,477 shares and may pressure sentiment by signaling insider profit-taking after the stock’s substantial advance. SEC insider sale filing
• Negative Sentiment: Another valuation article said Liquidia still appears expensive even as YUTREPIA expansion advances, raising the risk of a pullback if commercialization or regulatory progress falls short of expectations. Liquidia valuation concerns

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).